The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corbus Pharmaceuticals Holdings, Inc. (Corbus or the Company) (NASDAQ: CRBP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Corbus is the subject of a Seeking Alpha article published on February 28, 2019, entitled, Corbus Has Ties to Suspect Investors And A History Of Failed Clinical Trials for Lenabasum. According to the article, the Company has ties to investors convicted of or alleged to have committed securities fraud. The article also alleges that Corbus drug candidate, Lenabasum, has failed its major trials in [systemic sclerosis] and [cystic fibrosis]. Based on this news, shares of Corbus fell almost 16% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.